No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
391 |
4. Check minimum number of eventsNone |
391 |
5. Include endpointsNone |
391 |
6. Filter based on genotype QC (FinnGen only) |
391 |
Control definitions (FinnGen only)
- Control exclude
- RHEUMA_CHRYSTAL
Extra metadata
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- M11
- Name in latin
- Aliae chondrocalcinoses
Similar endpoints
↥List of similar endpoints to
Other chondrocalcinosis
based on the number of shared cases.
Similar with more cases:
- Other crystal arthropathies
- Crystal arthropathies, rheuma endpoint
- Polyarthropathies
- Finngen Rheumatological endpoints
- Arthropathies
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 2560 | 1394 | 1157 |
| Only index persons | 2391 | 1295 | 1096 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.04 | 0.04 | 0.03 |
| Only index persons | 0.04 | 0.05 | 0.04 |
| Median age at first event (years) | |||
| Whole population | 75.78 | 78.31 | 72.85 |
| Only index persons | 75.84 | 78.30 | 72.92 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 391 | 184 | 207 |
| Unadjusted period prevalence (%) | 0.08 | 0.06 | 0.09 |
| Median age at first event (years) | 73.44 | 73.62 | 73.28 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 350
- Matched controls
- 3501
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
M11.2
ICD-10 Finland
Other chondrocalcinosis
4503599627370496.0
323.0
344
*
M13.9
ICD-10 Finland
Arthritis, unspecified
27.8
112.7
162
105
TNX10
NOMESCO Finland
Arthrocentesis, unspecified region, unspecified region
15.1
62.4
110
103
H02AB06
ATC
prednisolone; systemic
6.0
50.3
266
1210
NK4XE
NOMESCO Finland
Joint ultrasound examination not elsewhere classified
10.8
40.8
83
98
M00.9
ICD-10 Finland
Pyogenic arthritis, unspecified
52.8
35.6
42
9
M17.1
ICD-10 Finland
Other primary gonarthrosis
4.0
29.0
154
579
NG1AA
NOMESCO Finland
Knee X-ray examination without contrast
5.0
27.6
101
263
M10.9
ICD-10 Finland
Gout, unspecified
6.5
27.0
75
140
P01BA02
ATC
hydroxychloroquine; oral
6.6
26.6
73
134
M17.0
ICD-10 Finland
Primary gonarthrosis, bilateral
4.1
24.2
111
356
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
4.9
23.5
86
220
L04AX03
ATC
methotrexate; systemic (immunosuppressants)
5.4
21.8
70
154
M25.5
ICD-10 Finland
Pain in joint
3.2
20.7
138
584
N02BE01
ATC
paracetamol; systemic, rectal
6.3
20.7
333
2644
A49.9
ICD-10 Finland
Bacterial infection, unspecified
4.0
18.9
85
261
M11.9
ICD-10 Finland
Crystal arthropathy, unspecified
+∞
18.9
18
*
N02AX02
ATC
tramadol; systemic, rectal
2.8
18.3
196
1106
ND2AA
NOMESCO Finland
Hand and fingers X-ray examination
4.7
17.7
64
159
B01AA03
ATC
warfarin; systemic
2.9
17.4
137
636
SPAT1263
SPAT
Sampling
2.7
17.1
191
1087
A02BC02
ATC
pantoprazole; systemic
2.8
16.8
266
1846
M01AH05
ATC
etoricoxib; oral
2.6
16.8
218
1348
M05.8
ICD-10 Finland
Other seropositive rheumatoid arthritis
5.5
16.7
51
105
J01DB01
ATC
cefalexin; oral
3.2
15.6
301
2300
TNG10
NOMESCO Finland
Puncture of knee
13.3
15.1
26
21
R50.9
ICD-10 Finland
Fever, unspecified
3.4
15.0
82
292
A46
ICD-10 Finland
Erysipelas
3.2
14.9
90
343
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
3.1
14.9
93
363
M11.8
ICD-10 Finland
Other specified crystal arthropathies
+∞
14.7
14
*
N02AA59
ATC
codeine, combinations excl. psycholeptics; systemic
2.4
14.3
181
1069
M15.9
ICD-10 Finland
Polyarthrosis, unspecified
4.8
14.2
49
115
B01AB05
ATC
enoxaparin; parenteral
2.5
13.6
147
793
NF1AA
NOMESCO Finland
Hip X-ray examination
3.7
13.4
63
198
S18
ICPC
Laceration/cut
2.4
13.4
188
1155
N02AJ06
ATC
codeine and paracetamol; systemic
2.4
13.3
150
824
M79.6
ICD-10 Finland
Pain in limb
2.4
13.1
155
871
NG1AE
NOMESCO Finland
Knee joint ultrasound exmination
20.0
13.1
19
10
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.3
12.5
205
1338
M17.9
ICD-10 Finland
Gonarthrosis, unspecified
3.2
12.2
71
260
M13.1
ICD-10 Finland
Monoarthritis, not elsewhere classified
18.9
12.2
18
10
A07EC01
ATC
sulfasalazine; oral, rectal
4.1
12.1
49
135
NGB20
NOMESCO Finland
Primary total prosthetic replacement of knee joint without patellar part
3.1
11.9
73
277
ACC51
NOMESCO Finland
Release of median nerve
4.7
11.7
40
93
NA3AA
NOMESCO Finland
Lumbar spine X-ray examination without contrast
3.4
11.7
59
195
EB1HA
NOMESCO Finland
Panorama tomography of teeth and jaws or similar X-ray examination
2.3
11.7
155
907
I48
ICD-10 Finland
Atrial fibrillation and flutter
2.3
11.6
139
773
J18.9
ICD-10 Finland
Pneumonia, unspecified
2.4
11.3
127
681
M01AH01
ATC
celecoxib; oral (coxibs)
2.7
11.3
86
374
C03CA01
ATC
furosemide; systemic
2.2
11.0
166
1021
R06.0
ICD-10 Finland
Dyspnoea
2.3
11.0
122
652
NG1DA
NOMESCO Finland
X-ray of knees
8.4
10.8
23
29
L15
ICPC
Knee symptom/complaint
2.4
10.7
105
523
SPAT1153
SPAT
Removal of sutures
2.2
10.7
147
864
M06.9
ICD-10 Finland
Rheumatoid arthritis, unspecified
6.1
10.5
28
49
ND2DA
NOMESCO Finland
Bilateral hand X-ray examination
8.6
10.5
22
27
NG1BA
NOMESCO Finland
Knee extensive X-ray examination
7.5
10.5
24
34
G56.0
ICD-10 Finland
Carpal tunnel syndrome
3.2
10.4
58
206
SPAT1148
SPAT
Treatment of chronic ulcer or burn
2.6
10.2
83
374
PH2AE
NOMESCO Finland
Ultrasound examination of lower leg veins
3.0
10.0
63
242
M10.0
ICD-10 Finland
Idiopathic gout
5.4
9.8
29
58
NGB40
NOMESCO Finland
Primary total prosthetic replacement of knee joint with patellar part - sliding prosthesis
5.6
9.6
27
51
SPAT1253
SPAT
Initiation, adjustment, discontinuation or repetition of medication
2.2
9.6
131
760
L90
ICPC
Osteoarthrosis of knee
3.7
9.5
42
125
K78
ICPC
Atrial fibrillation/flutter
3.0
9.5
58
219
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
2.4
9.4
95
477
NH3DA
NOMESCO Finland
Bilateral foot X-ray examination
7.6
9.4
21
29
M01AX05
ATC
glucosamine; oral
2.2
9.3
111
605
M02.9
ICD-10 Finland
Reactive arthropathy, unspecified
10.4
9.1
17
17
SPAT1149
SPAT
Suture or treatment of traumatic wound
2.5
9.1
76
346
M75.1
ICD-10 Finland
Rotator cuff syndrome
2.3
9.1
95
485
M13.0
ICD-10 Finland
Polyarthritis, unspecified
13.0
8.9
15
12
N03AX12
ATC
gabapentin; oral
2.5
8.7
71
318
N03AX16
ATC
pregabalin; oral
2.2
8.5
101
545
M04AA01
ATC
allopurinol; systemic
2.4
8.5
77
365
FM1EE
NOMESCO Finland
Extensive structural and functional ultrasound examination of heart
2.2
8.4
104
570
L88
ICPC
Rheumatoid/seropositive arthritis
5.0
8.4
26
55
M05.9
ICD-10 Finland
Seropositive rheumatoid arthritis, unspecified
5.9
8.3
22
39
NK4AT
NOMESCO Finland
Puncture of joint with ultrasound guidance not elsewher classified
17.7
8.1
12
7
NH3EA
NOMESCO Finland
Feet X-ray examination with load
7.5
8.1
18
25
M51.3
ICD-10 Finland
Other specified intervertebral disc degeneration
3.7
8.1
34
98
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
2.2
8.1
89
464
C07AB07
ATC
bisoprolol; oral
1.9
8.0
207
1504
NH3AA
NOMESCO Finland
Foot and toes X-ray examination
3.0
7.9
45
162
M06.0
ICD-10 Finland
Seronegative rheumatoid arthritis
5.3
7.9
23
46
NB1AA
NOMESCO Finland
Shoulder X-ray examination without contrast
3.3
7.8
38
123
M19.0
ICD-10 Finland
Primary arthrosis of other joints
2.9
7.8
48
181
SPAT1254
SPAT
Administration of medicine
2.3
7.8
81
409
L12
ICPC
Hand/finger symptom/complaint
2.6
7.7
60
259
L11
ICPC
Wrist symptom/complaint
3.5
7.7
35
108
NF1AE
NOMESCO Finland
Hip joint ultrasound examination
6.4
7.7
19
31
290
Kela drug reimbursment
Apixaban, dabigatran, edoxaban and rivaroxaban for the treatment of atrial fibrillation
2.2
7.6
84
434
M35.3
ICD-10 Finland
Polymyalgia rheumatica
3.7
7.5
32
93
ND2BA
NOMESCO Finland
Hand and fingers extensive X-ray examination
7.1
7.4
17
25
L08
ICPC
Shoulder symptom/complaint
2.2
7.4
79
405
Y88.3
ICD-10 Finland
Sequelae of surgical and medical procedures as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure
5.3
7.2
21
42
J01CA04
ATC
amoxicillin; systemic
2.0
7.2
264
2138
NE1AA
NOMESCO Finland
Pelvis X-ray examination
2.9
7.2
42
155
M48.0
ICD-10 Finland
Spinal stenosis
2.3
6.9
68
334
NJ2MA
NOMESCO Finland
Measurement of mechanical axis of lower leg with X-ray
2.9
6.9
43
163
N02AA05
ATC
oxycodone; systemic
2.1
6.9
83
445
NK6QA
NOMESCO Finland
Measurement of bone density from tow or more locations with X-ray
3.2
6.9
35
118
1220
FHL
Arthroscopy
4.1
6.8
25
64
NH1AA
NOMESCO Finland
Ankle X-ray examination without contrast
3.3
6.8
33
107
N10
ICD-10 Finland
Acute tubulo-interstitial nephritis
2.3
6.8
67
329
SPAT1249
SPAT
Treatment-related counselling outside office
1.8
6.8
153
1038
SPAT1223
SPAT
Implementation of physical therapy rehabilitation plan
1.9
6.7
124
787
D64.9
ICD-10 Finland
Anaemia, unspecified
2.5
6.7
52
228
W01
ICD-10 Finland
Fall on same level from slipping, tripping and stumbling
1.9
6.6
128
827
M17.3
ICD-10 Finland
Other post-traumatic gonarthrosis
7.1
6.6
15
22
M13.8
ICD-10 Finland
Other specified arthritis
10.3
6.6
12
12
SAA02
NOMESCO Finland
Basic examination of mouth
1.8
6.6
190
1397
L01
ICPC
Neck symptom/complaint
2.4
6.6
56
256
M17
ICD-10 Finland
Gonarthrosis [arthrosis of knee]
2.5
6.5
53
234
L20
ICPC
Joint symptom/complaint NOS
4.9
6.5
20
43
L17
ICPC
Foot/toe symptom/complaint
1.9
6.5
105
632
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
1.8
6.5
143
964
M19.9
ICD-10 Finland
Arthrosis, unspecified
3.9
6.4
25
68
M10
ICD-10 Finland
Gout
3.5
6.4
28
84
B01AF02
ATC
apixaban; oral
2.4
6.3
55
254
C01DA08
ATC
isosorbide dinitrate; oral, oral aerosol, sublingual, transdermal
1.9
6.3
117
741
SPAT1256
SPAT
Intramuscular and subcutaneous injection
1.8
6.3
167
1187
72410
ICD-8 Finland
Internal derangement of joint, Other shoulder derangement
4.7
6.3
20
45
A03
ICPC
Fever
2.5
6.2
49
217
WZA10
NOMESCO Finland
Long statement of health and health related matters
12.8
6.1
10
8
TPH04
NOMESCO Finland
Cathetrisation of vein
2.0
6.1
88
505
R60.0
ICD-10 Finland
Localized oedema
2.3
6.1
56
267
J01FF01
ATC
clindamycin; systemic
1.9
6.1
96
573
I50.9
ICD-10 Finland
Heart failure, unspecified
2.0
6.1
81
453
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
192
94
39.17
271.20
2.0
1.3
—
—
—
0
0
148
80
29.16
197.15
2.5
1.5
33495.5
15227.0
e6/l
1.21
118
57
88
32
35.20
133.62
1.7
1.3
76.6
62.6
%
1.45
69
25
72
29
30.21
104.90
2.1
1.2
19.3
32.7
%
1.17
57
21
68
30
27.23
95.60
1.8
1.2
73116.8
285732.8
e6/l
0.39
53
21
252
870
6.33
72.17
3.8
2.9
1741.9
9927.5
umol/l
2.82
224
730
170
426
6.29
69.40
1.5
1.3
21.0
14.0
u/ml
0.39
65
156
166
466
5.45
58.20
1.5
1.3
25.8
41.9
iu/ml
1.22
63
145
74
99
8.99
54.11
1.9
1.5
—
—
—
0
0
167
583
4.25
42.26
3.1
2.4
11.6
12.2
umol/l
0.46
153
528
156
529
4.24
40.88
3.1
2.4
2.2
2.3
g/l
1.95
143
482
146
505
4.02
36.64
3.3
2.4
22.5
21.6
%
0.33
128
427
301
1791
3.96
30.93
11.0
8.8
4.9
4.3
e9/l
3.60
275
1571
48
76
7.06
29.80
1.8
1.5
—
—
—
0
0
288
1762
3.41
26.18
9.0
7.2
1.2
1.2
mmol/l
0.00
246
1482
274
1631
3.27
26.05
8.0
6.3
1.2
1.2
mmol/l
0.12
257
1468
226
1239
2.95
24.30
3.9
2.7
161.9
153.9
ug/l
0.23
203
1111
349
2494
4.72
23.21
10.9
7.6
80.8
81.0
u/l
0.02
340
2322
95
325
3.54
23.09
1.9
2.6
65.4
66.0
g/l
0.32
89
291
334
2321
4.01
23.06
9.3
4.2
21.5
14.4
mm/h
7.73
318
2104
180
904
2.84
22.34
2.9
2.2
3.8
3.3
mg/l
1.47
156
770
209
1233
2.49
17.47
4.5
3.2
2279.4
1673.1
ng/l
1.21
185
1073
77
276
3.23
17.03
4.6
3.7
96.9
87.5
ng/l
0.36
63
245
261
1745
2.49
16.01
5.9
6.4
10.6
11.9
umol/l
1.78
251
1640
240
1551
2.42
15.80
5.8
4.2
0.0
0.0
estimate
0.00
73
297
372
3025
5.73
15.47
34.8
17.7
29.2
26.3
mg/l
1.08
352
2461
283
1993
2.52
15.02
5.9
5.4
6.8
6.9
mmol/l
0.33
270
1868
55
176
3.47
14.49
2.5
1.8
0.4
3.2
ug/l
1.01
48
155
38
94
4.37
14.35
1.3
1.2
4.1
2.1
u/ml
—
8
9
226
1461
2.30
14.33
6.1
4.3
44.6
65.3
ng/l
0.38
190
1134
300
2194
2.58
14.28
7.1
5.1
149.6
3338.2
e6/l
—
9
53
236
1561
2.29
14.06
7.6
5.6
0.0
0.0
estimate
0.00
72
287
116
567
2.49
14.04
3.0
3.3
0.8
0.8
mmol/l
0.66
110
528
205
1283
2.26
13.93
2.9
2.3
81.2
78.2
nmol/l
0.76
186
1109
237
1579
2.27
13.76
6.1
4.3
0.0
0.0
estimate
0.00
73
282
205
1298
2.22
13.36
4.6
3.4
—
—
—
0
0
189
1180
2.16
12.52
2.9
3.5
2.3
2.3
mmol/l
0.13
164
1017
153
884
2.20
12.28
6.6
4.6
0.0
0.0
estimate
0.00
70
280
176
1075
2.16
12.27
2.7
2.0
161.6
270.1
u/l
0.83
170
1000
139
789
2.18
11.53
2.3
1.8
1233.9
1182.7
nmol/l
0.26
106
587
127
696
2.22
11.49
1.8
1.7
1.2
1.4
mg/l
0.52
101
563
223
1522
2.08
11.28
5.6
4.9
32.6
34.7
g/l
6.37
206
1408
117
627
2.24
11.14
2.2
1.9
—
—
—
0
0
40
127
3.39
10.61
3.0
3.7
38.6
36.4
mg/l
0.08
33
100
40
127
3.39
10.61
3.0
3.7
39.5
109.0
mg/l
0.73
32
99
186
1212
2.02
10.43
6.6
4.6
—
—
—
0
0
101
525
2.25
10.26
40.9
28.9
1.5
1.4
inr
—
8
66
49
180
2.97
10.21
1.8
2.2
1.6
1.6
g/l
0.00
44
160
33
95
3.70
10.13
1.8
1.5
—
—
—
0
0
370
3183
4.02
10.12
34.8
21.4
139.2
139.6
mmol/l
2.00
361
3095
215
1488
1.99
10.02
4.9
4.5
—
—
—
0
0
369
3173
3.90
10.01
18.3
11.3
22.8
24.3
u/l
1.25
362
3041
370
3189
3.98
9.95
35.1
21.4
4.0
4.0
mmol/l
0.28
361
3099
38
124
3.29
9.65
3.1
3.6
1.3
3.0
ratio
—
7
9
292
2272
2.13
9.57
4.0
3.8
15.5
15.1
pmol/l
1.62
251
1982
25
63
4.17
9.20
1.1
1.3
—
—
—
0
0
157
1003
1.94
8.98
4.0
3.3
0.5
0.5
e6/l
0.06
135
763
55
231
2.61
8.89
1.6
1.5
—
—
—
0
0
162
1052
1.92
8.77
2.6
2.6
50.9
57.7
u/l
2.35
153
975
240
1775
1.91
8.67
3.7
3.3
69.8
57.8
u/l
0.61
220
1616
65
302
2.38
8.47
5.6
4.2
1.2
1.2
mmol/l
0.39
60
265
18
37
5.05
8.44
1.2
1.2
—
—
—
0
0
29
87
3.52
8.38
1.4
1.4
0.0
0.1
iu/ml
—
10
21
331
2768
2.28
8.09
5.1
4.7
7.5
2.5
mu/l
0.45
296
2438
27
80
3.55
7.95
2.2
2.0
12.7
13.2
mg/l
0.07
27
74
37
136
2.90
7.69
2.4
1.8
—
—
—
0
0
59
274
2.36
7.67
2.0
1.8
—
—
—
0
0
335
2833
2.27
7.67
26.6
16.6
71.2
72.4
ml/min/173m2
0.42
296
2351
203
1463
1.81
7.56
2.4
2.1
100.6
92.6
pmol/l
1.38
115
747
30
100
3.17
7.37
1.7
1.6
—
—
—
0
0
125
789
1.86
7.10
2.5
2.5
—
—
—
0
0
39
154
2.70
7.10
1.2
1.4
—
38.9
—
0
10
34
125
2.88
7.06
2.2
1.6
—
—
—
0
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
34
126
2.86
6.97
2.9
2.3
0.4
0.4
u/ml
0.05
21
67
196
1426
1.75
6.84
2.7
2.3
—
—
—
0
0
29
102
2.99
6.52
3.3
3.2
0.8
0.9
nmol/l
0.74
24
80
36
146
2.61
6.23
1.6
2.3
3.6
3.2
g/l
1.18
29
114
333
2875
2.07
6.19
6.8
6.6
40.5
41.3
mmol/mol
0.86
299
2616
23
74
3.24
5.99
1.3
1.2
1.5
3.0
u/ml
—
6
10
122
801
1.76
5.92
2.0
1.8
450.2
8920623.8
pmol/l
0.50
103
639
16
41
4.03
5.77
1.2
1.4
167834.4
213732.7
e6/l
—
9
22
23
76
3.15
5.75
1.3
1.2
2.5
1.9
u/ml
—
8
12
134
911
1.72
5.72
1.8
1.6
20.7
20.8
nmol/l
0.00
113
756
37
159
2.47
5.69
1.6
2.2
3.8
3.7
g/l
0.39
29
112
37
160
2.45
5.62
1.6
2.2
—
—
—
0
0
37
160
2.45
5.62
1.6
2.2
7.8
7.5
g/l
0.34
32
116
70
392
1.96
5.61
4.4
3.7
—
—
—
0
0
79
461
1.89
5.60
3.5
8.4
1.7
1.5
mmol/l
0.14
58
362
12
25
4.92
5.53
2.7
4.1
—
—
—
0
0
45
214
2.25
5.53
5.8
3.8
1.6
2.0
mmol/l
0.21
32
163
342
3018
2.06
5.43
5.3
5.4
2.4
2.6
mmol/l
2.80
309
2697
338
2975
2.00
5.33
5.3
5.1
5.9
6.1
mmol/l
2.75
305
2643
55
289
2.05
5.25
2.4
1.9
336.2
374.9
nmol/l
0.67
48
260
19
61
3.22
4.98
1.4
1.3
—
—
—
0
0
32
137
2.45
4.98
2.0
2.9
—
—
—
0
0
89
565
1.74
4.75
1.3
1.2
0.7
1.5
u/ml
1.27
28
157
287
2437
1.67
4.72
33.1
21.8
14.4
13.9
%
7.10
280
2387
328
2900
1.81
4.52
4.9
4.7
1.5
1.4
mmol/l
0.06
296
2584
45
233
2.05
4.47
2.0
1.6
—
—
—
0
0
74
455
1.77
4.39
2.1
1.9
—
—
—
0
0
318
2798
1.73
4.32
4.5
4.3
1.2
1.3
mmol/l
0.93
284
2476
8
9
9.04
4.30
1.1
1.2
173.0
79.8
iu/ml
—
8
9
19
68
2.89
4.18
1.3
1.1
—
—
—
0
0
67
410
1.77
4.03
5.3
4.8
35.5
32.0
%
1.74
54
257
72
450
1.74
4.03
2.0
1.9
—
—
—
0
0
26
112
2.42
4.02
1.8
2.5
0.0
0.0
g/l
0.00
26
102
11
28
4.01
4.00
1.3
1.1
—
—
—
0
0
328
2929
1.74
3.99
5.0
4.8
4.3
4.5
mmol/l
2.22
297
2638
15
48
3.21
3.97
1.1
1.0
—
—
—
0
0
9
15
6.11
3.83
2.9
2.4
—
—
—
0
0
59
357
1.77
3.69
3.1
2.6
3.8
6.5
ug/l
1.63
45
315
13
41
3.25
3.52
1.2
1.5
—
—
—
0
0
45
254
1.87
3.52
2.5
3.0
58.6
56.7
ml/min/173m2
0.13
22
107
58
358
1.73
3.38
5.5
3.8
1.4
1.9
mmol/l
0.43
50
279
17
65
2.69
3.35
1.2
1.8
—
—
—
0
0
13
43
3.09
3.28
1.4
1.5
—
—
—
0
0
13
43
3.09
3.28
1.4
1.5
—
—
—
0
0
144
1108
1.47
3.28
4.0
4.0
20.6
8.6
mg/mmol
1.15
100
715
89
620
1.56
3.23
3.9
2.9
0.7
1.2
e6/l
1.79
52
360
7
11
6.46
3.20
1.0
1.0
—
—
—
0
0
20
87
2.37
3.06
1.2
1.7
—
—
—
0
0
100
726
1.51
2.99
2.7
3.2
2.5
2.5
mmol/l
0.80
89
630
20
88
2.34
2.99
1.2
1.7
—
—
—
0
0
10
30
3.39
2.92
1.1
1.8
—
—
—
0
0
10
30
3.39
2.92
1.1
1.8
—
—
—
0
0
10
30
3.39
2.92
1.1
1.8
—
—
—
0
0
18
78
2.37
2.79
1.6
1.4
—
—
—
0
0
18
78
2.37
2.79
1.6
1.4
—
—
—
0
0
5
6
8.42
2.75
1.2
1.0
—
—
—
0
0
24
120
2.07
2.67
1.3
1.3
—
—
—
0
0
12
43
2.85
2.67
1.4
1.5
—
—
—
0
0
12
43
2.85
2.67
1.4
1.5
—
—
—
0
0
10
32
3.18
2.66
1.5
1.1
1.6
1.6
u/ml
—
5
9
15
62
2.48
2.57
1.1
1.1
—
14.8
—
0
7
12
44
2.78
2.57
1.4
1.5
—
—
—
0
0
17
76
2.29
2.48
1.4
1.4
—
—
—
0
0
62
425
1.55
2.41
16.0
8.3
—
—
—
0
0
14
58
2.47
2.39
1.4
1.6
—
—
—
0
0
14
59
2.42
2.32
1.4
1.6
—
—
—
0
0
7
18
3.94
2.26
1.0
1.0
—
—
—
0
0
17
81
2.15
2.16
1.1
1.5
—
—
—
0
0
18
88
2.10
2.15
1.2
1.7
—
—
—
0
0
8
25
3.24
2.10
1.0
1.2
—
—
—
0
0
5
10
5.05
2.07
1.6
1.2
—
—
—
0
0
7
20
3.54
2.06
1.4
1.8
—
—
—
0
0
15
70
2.19
2.01
1.3
1.6
—
—
—
0
0
7
21
3.37
1.97
1.4
1.8
—
—
—
0
0
8
27
3.00
1.94
1.4
1.7
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
6
16
3.79
1.94
1.0
1.1
—
—
—
0
0
45
302
1.55
1.93
2.3
2.5
25.2
31.8
u/l
1.35
33
248
157
1318
1.32
1.91
4.9
5.4
2.9
3.0
ug/l
0.07
134
1155
16
79
2.07
1.88
2.6
2.7
16.0
15.2
%
—
7
35
10
40
2.54
1.85
7.0
2.3
—
—
—
0
0
6
17
3.57
1.84
1.5
1.4
—
—
—
0
0
6
17
3.57
1.84
1.5
1.4
—
—
—
0
0
12
53
2.30
1.82
1.4
1.7
—
—
—
0
0
23
132
1.79
1.78
1.2
1.1
53.9
128.9
iu/ml
—
8
45
280
2564
1.32
1.72
30.3
19.3
37.3
38.5
%
1.01
148
1585
16
82
1.99
1.72
2.1
2.7
4.0
3.7
g/l
0.31
16
77
12
56
2.18
1.62
1.0
1.1
3.5
3.9
mmol/l
0.91
12
51
5
14
3.60
1.62
2.4
1.6
42.4
57.4
ug/l
—
5
14
8
32
2.53
1.60
1.4
1.8
—
—
—
0
0
8
33
2.45
1.54
1.1
1.9
—
—
—
0
0
5
15
3.36
1.53
1.0
2.0
—
—
—
0
0
5
15
3.36
1.53
1.2
1.0
—
—
—
0
0
5
15
3.36
1.53
1.0
2.0
—
—
—
0
0
5
15
3.36
1.53
1.0
2.0
—
—
—
0
0
5
15
3.36
1.53
1.0
2.0
—
—
—
0
0
7
28
2.53
1.46
2.1
3.2
20.0
75.3
u/ml
—
7
28
5
16
3.15
1.44
1.0
1.3
—
—
—
0
0
7
29
2.44
1.40
1.0
1.1
—
—
—
0
0
11
53
2.11
1.40
1.2
1.4
—
—
—
0
0
6
23
2.63
1.37
1.3
1.5
—
—
—
0
0
6
23
2.63
1.37
1.3
1.5
—
—
—
0
0
6
24
2.52
1.31
1.5
1.4
—
—
—
0
0
6
24
2.52
1.31
1.0
1.0
—
3.2
—
0
9
6
24
2.52
1.31
1.5
1.4
—
—
—
0
0
8
34
2.38
1.30
1.1
1.9
—
—
—
0
0
5
18
2.80
1.29
1.0
2.1
—
14.6
—
0
8
5
18
2.80
1.29
1.0
1.1
1.7
2.0
mmol/l
—
5
18
11
55
2.03
1.28
1.4
1.6
—
—
—
0
0
9
44
2.07
1.27
1.3
1.7
—
—
—
0
0
5
20
2.52
1.15
1.0
1.0
—
—
—
0
0
5
22
2.29
1.03
1.2
1.0
—
—
—
0
0
7
35
2.02
1.00
1.3
1.3
—
—
—
0
0
49
383
1.32
0.99
2.2
3.1
6.2
8.6
umol/l
1.33
43
332
16
100
1.63
0.98
1.3
1.4
—
—
—
0
0
0
29
0.00
0.98
0.0
1.1
—
1.6
—
0
23
10
55
1.84
0.93
1.1
1.1
—
—
—
0
0
6
29
2.09
0.89
1.0
1.1
—
—
—
0
0
8
42
1.92
0.89
1.6
1.2
—
—
—
0
0
18
121
1.51
0.84
1.3
1.3
—
—
—
0
0
110
964
1.20
0.84
2.3
3.2
37.6
33.1
u/l
0.43
104
922
0
24
0.00
0.79
0.0
1.2
—
11.4
—
0
7
14
90
1.58
0.79
1.1
1.3
—
—
—
0
0
69
581
1.23
0.79
4.3
3.2
2.3
2.2
e6/l
0.06
31
324
15
99
1.54
0.76
1.2
1.2
—
—
—
0
0
15
99
1.54
0.76
1.2
1.2
—
—
—
0
0
51
418
1.25
0.74
2.2
4.3
4.1
35.1
ug/l
1.03
44
359
87
760
1.19
0.69
3.0
3.1
0.7
0.8
ug/l
1.99
55
521
5
29
1.73
0.64
1.0
1.0
—
—
—
0
0
31
245
1.29
0.62
4.4
3.4
117.9
124.0
g/l
1.06
31
240
20
265
0.74
0.60
1.3
1.3
—
—
—
0
0
6
39
1.55
0.53
1.2
1.5
—
—
—
0
0
12
84
1.44
0.50
1.8
1.6
—
—
—
0
0
8
118
0.67
0.46
2.0
1.8
—
—
—
0
0
73
813
0.87
0.45
1.8
1.7
1.3
1.3
mmol/l
0.52
57
655
0
15
0.00
0.41
0.0
1.3
—
—
—
0
0
5
34
1.48
0.40
1.6
1.3
—
—
—
0
0
16
125
1.29
0.37
1.0
1.0
—
—
—
0
0
5
37
1.36
0.37
10.4
2.7
—
—
—
0
0
5
37
1.36
0.37
1.2
1.1
—
—
—
0
0
11
81
1.37
0.36
3.2
2.3
125.9
125.3
g/l
0.04
11
60
6
41
1.47
0.36
2.0
2.7
5.1
7.8
nmol/l
—
6
41
34
294
1.17
0.34
1.3
1.3
—
—
—
0
0
18
147
1.24
0.31
1.4
1.2
187.8
194.4
u/ml
0.02
18
134
7
56
1.25
0.29
1.0
1.2
—
—
—
0
0
12
94
1.29
0.28
2.7
2.7
8.1
7.7
kpa
0.29
12
84
112
1061
1.08
0.25
4.4
4.7
18.2
21.5
%
1.73
60
555
0
11
0.00
0.21
0.0
2.4
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
6
53
1.13
0.18
1.3
1.7
—
—
—
0
0
76
722
1.07
0.16
5.1
4.0
74.5
276.9
ng/l
2.42
66
628
5
46
1.09
0.09
4.4
4.1
—
—
—
0
0
0
9
0.00
0.00
0.0
1.1
—
—
—
0
0
0
9
0.00
0.00
0.0
1.1
—
—
—
0
0
0
8
0.00
0.00
0.0
1.4
—
—
—
0
0
0
9
0.00
0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
9.1
—
0
5
0
5
0.00
0.00
0.0
1.0
—
88.2
—
0
5
0
7
0.00
0.00
0.0
1.4
—
—
—
0
0
0
6
0.00
0.00
0.0
3.5
—
96.5
—
0
6
0
5
0.00
0.00
0.0
1.0
—
4.0
—
0
5
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint CHONDRO_OTH and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| CHONDRO_OTH | 1.335 [1.09, 1.63] | 0.004 |
| Birth year | 0.997 [0.99, 1.01] | 0.533 |
During the follow-up period (1.1.1998 — 31.12.2019), 447 out of 1101 females with CHONDRO_OTH died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| CHONDRO_OTH | 1.598 [1.24, 2.05] | < 0.001 |
| Birth year | 0.986 [0.98, 1.0] | 0.004 |
During the follow-up period (1.1.1998 — 31.12.2019), 335 out of 887 males with CHONDRO_OTH died.
Mortality risk
Mortality risk for people of age
years, who have CHONDRO_OTH.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.165% | 0.255% |
| 5 | 0.921% | 1.688% |
| 10 | 2.104% | 4.222% |
| 15 | 4.053% | 8.131% |
| 20 | 7.215% | 13.94% |
Relationships between endpoints
↥Index endpoint: CHONDRO_OTH – Other chondrocalcinosis
GWS hits: 1
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data